Heart Disease Clinical Trials in San Francisco

Showing 161-167 of 167 trials

Biomarkers in Acute Heart Failure

NCT00537628

Primary Objectives 1. Mid Region pro Adrenomedullin (MR-proADM) is superior to BNP for the prognosis of heart failure (HF) patients and adds incremental value in predicting outcomes for patients presenting to the Emergency Department (ED) with shortness of breath. 2. Mid Region pro A-Type Natriuretic Peptide (MR-proANP) is non-inferior to BNP for the diagnosis of HF in patients presenting to the ED with shortness of breath.

Shortness of BreathHeart Failure

Brahms AG1,641 participantsStarted Mar 2007

San Diego, California, United States • San Diego, California, United States • San Francisco, California, United States +12 more locations

TERMINATED< 1 mile

Long-Term Follow-up Study of Patients Who Received PB127 Ultrasound Imaging Agent

NCT00584714

The purpose of this study is to collect longer term follow-up information concerning health and survival on selected patients who received PB127 for injectable suspension in the pivotal trial (127-014).

Coronary Artery Disease

Point Biomedical300 participantsStarted Oct 2007

Tucson, Arizona, United States • Burlingame, California, United States • Long Beach, California, United States +36 more locations

Biomarkers in Acute Heart Failure

Long-Term Follow-up Study of Patients Who Received PB127 Ultrasound Imaging Agent

Heart Disease Trials in Other Cities

Exercise Training in Older Diabetic Women

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.

Obesity Prevention for Pre-Adolescents

ARISE - Aggressive Reduction of Inflammation Stops Events

Other Conditions in San Francisco